Pharmacokinetic-Pharmacodynamic Relationships of (2S,3S)-Valnoctamide and Its Stereoisomer (2R,3S)-Valnoctamide in Rodent Models of Epilepsy

@article{Isoherranen2004PharmacokineticPharmacodynamic,
  title={Pharmacokinetic-Pharmacodynamic Relationships of (2S,3S)-Valnoctamide and Its Stereoisomer (2R,3S)-Valnoctamide in Rodent Models of Epilepsy},
  author={Nina Isoherranen and H. Steve White and Brian D. Klein and Michael Roeder and Jos{\'e} H. Woodhead and Volker Schurig and Boris Yagen and Meir Bialer},
  journal={Pharmaceutical Research},
  year={2004},
  volume={20},
  pages={1293-1301}
}
AbstractPurpose. Racemic valnoctamide (VCD) is a central nervous system- active drug commercially available in Europe. VCD possesses two chiral centers and, therefore, it exists as a mixture of four stereoisomers. The purpose of this study was to evaluate the anticonvulsant activity of two VCD stereoisomers in comparison with VCD (racemate), valpromide (VPD), and valproic acid (VPA) and to study their pharmacokinetic-pharmacodynamic relationships. Methods. The ability of racemic VCD, (2S,3S… 

Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid.

2,2,3,3-Tetramethylcyclopropanecarboxylic acid (TMCA, 4) is a cyclic analogue of the antiepileptic drug (AED) valproic acid (VPA) (1). alpha-F, alpha-Cl, alpha-Br, and alpha-methyl derivatives of 4

Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain

TLDR
VCD, DID and VPD are nonteratogenic, potentially nonhepatotoxic, and exhibit better anticonvuslant potency than VPA, and have potential to become new drugs for the treatment of neuropathic pain.

Valnoctamide and sec‐butyl‐propylacetamide (SPD) for acute seizures and status epilepticus

TLDR
SPD possesses a unique and broad‐spectrum antiseizure profile superior to that of valproic acid (VPA) and better than that of VCD, and differentiates SPD from benzodiazepines and all other antiepileptic drugs.

Valproic acid: Second generation

New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?

TLDR
Three compounds in clinical trials in patients with epilepsy that can be regarded as second-generation VPA: valproyl glycinamide, 3-methylbutanamide or isovaleramide and SPD421 (DP-VPA).

Diverse mechanisms of antiepileptic drugs in the development pipeline

References

SHOWING 1-10 OF 31 REFERENCES

Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.

TLDR
Monitoring the levels of these two amide isomers in the brain, liver, plasma, and urine of rats found that VCD and VPD distribute better into the brain than VPA, a fact that may contribute to their better anticonvulsant activity.

Stereoselective Pharmacokinetic Analysis of Valnoctamide, a CNS-Active Chiral Amide Analogue of Valproic Acid, in Dogs, Rats, and Mice

TLDR
The stereoselective pharmacokinetics of VCD as observed in dogs, rats, and mice is in line with the stereoselectedivity previously observed in healthy subjects and epileptic patients.

Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity.

TLDR
Significant differences were observed in their pharmacokinetics and in the fraction of the amide (fm) biotransformed to its homologous acid, which may account for the observed differences in the respective pharmacological activities.

Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents

TLDR
It is demonstrated that PID has both enantioselective pharmacokinetics and pharmacodynamics and the enhanced efficacy of the racemate over the individual enantiomers in the kindled rat may be explained by a pharmacokinetic enantiomer–enantiomer interaction in rats.

Structure–Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepileptic Activity

TLDR
This study showed that these amides need an unsubstituted β position in their aliphatic side chain in order to biotransform to their homologous acids, and showed that an amide which is not metabolized is more potent as an anticonvulsant than itsBiotransformed isomer.

New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?

TLDR
Three compounds in clinical trials in patients with epilepsy that can be regarded as second-generation VPA: valproyl glycinamide, 3-methylbutanamide or isovaleramide and SPD421 (DP-VPA).

Carbamazepine‐Valnoctamide Interaction in Epileptic Patients: In Vitro/In Vivo Correlation

TLDR
In this study, VCD clearance was higher in epileptic patients (treated with CBZ) than in healthy subjects, and there was a striking similarity between in vitro and in vivo inhibition potencies.

Clinical Pharmacology of Valpromide

  • M. Bialer
  • Medicine, Biology
    Clinical pharmacokinetics
  • 1991
TLDR
The pharmacokinetics of valpromide, the interactions between it and other drugs such as carbamazepine and amitriptyline, and its antiepileptic and antipsychotic activities are discussed.